作者
Monique HE Reijers, Gerrit Jan Weverling, Suzanne Jurriaans, Ferdinand WNM Wit, Hugo M Weigel, Reinier W Ten Kate, Jan Willem Mulder, PH Jos Frissen, Remko van Leeuwen, Peter Reiss, Hanneke Schuitemaker, Frank de Wolf, Joep MA Lange
发表日期
1998/7/18
期刊
The Lancet
卷号
352
期号
9123
页码范围
185-190
出版商
Elsevier
简介
Background
Highly active antiretroviral therapy (HAART) has led to health benefits for patients infected with HIV-1. However, long-term use of multidrug regimens is difficult to sustain. Simplifying antiretroviral treatment regimens would increase patients' adherence and minimise toxicity. We investigated the feasibility of a strategy of induction therapy followed by maintenance therapy with HAART in a randomised open-label study.
Methods
From March, 1997, we enrolled patients infected with HIV-1 with at least 200 CD4cells/μL, at least 1000 HIV-1 RNA copies/mL in plasma, and no previous exposure to antiretroviral drugs. After 26 weeks of induction therapy (stavudine, lamivudine, saquinavir, and nelfinavir) patients were randomly allocated maintenance therapy (either stavudine and nelfinavir or saquinivir and nelfinavir) or prolonged induction therapy (if the plasma HIV-1 RNA concentration at weeks 24 and 25 was …
引用总数
学术搜索中的文章
MHE Reijers, GJ Weverling, S Jurriaans, FWNM Wit… - The Lancet, 1998